|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||25.54 - 25.90|
|52 Week Range||21.32 - 29.93|
|PE Ratio (TTM)||42.26|
|Earnings Date||Feb 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.32|
A few weeks ago, Boston Scientific announced that its expected launch of Lotus Heart Valve in the EU and U.S. in early 2018 will be delayed. This spooked investors somewhat, and has contributed to a more than 10% decline in the stock price since then.
Boston Scientific Corp. announced U.S. regulators have approved its Vercise Deep Brain Stimulation System to treat patients with Parkinson’s disease Monday, boosting its share price nearly 3 percent in after-hours trading. The device, which stimulates a specific area of the brain using implanted leads, was shown in a U.S. trial to help improve the number of waking hours per day in patients with the disease, according to the company. In another study in Europe, it helped patients achieve a 63 percent improvement in motor function over the course of a year, as measured by a common rating system to measure severity of Parkinson’s disease.
MARLBOROUGH, Mass., Dec. 11, 2017 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Vercise™ Deep Brain Stimulation (DBS) System. DBS is used to treat the symptoms of Parkinson's disease (PD), a degenerative condition that affects more than one million people in the United States and 10 million worldwide.1 DBS works by stimulating a targeted region of the brain through implanted leads that are powered by a device called an implantable pulse generator (IPG).
Shares of medical device maker Boston Scientific Corporation (NYSE: BSX ) received a top-notch rating Friday from Needham. The Analyst Needham analyst Mike Matson upgraded shares of Boston Scientific from ...
NEW YORK, Dec. 05, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CME ...
Boston Scientific (BSX) announced its deal to acquire Apama Medical and strengthen its electrophysiology portfolio on October 2, 2017.
Since the company's news of the delay in relaunch of Lotus Edge on November 28, 2017, Boston Scientific (BSX) stock has fallen ~7.8%.
MARLBOROUGH, Mass. , Dec. 4, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the BMO Capital Markets Prescriptions for Success Healthcare Conference on December 14, 2017 ...
According to Boston Scientific, the delay will have no material impact on the company's fiscal 4Q17 and 2017 results.
Boston Scientific (BSX) announces a delay in deadline for the commercial return of the LOTUS Edge Aortic Valve System in Europe. Following this news, share price declines.
Boston Scientific (BSX) announced the delay in the commercialization timelines of BSX's Lotus devices in Europe and the US on November 28, 2017.
Boston Scientific dipped Wednesday after announcing another delay for its heart-valve replacement product, called Lotus Edge.
Shares of the worldwide developer, manufacturer, and marketer of medical devices were sent lower on Tuesday after it delayed the commercialization of its Lotus Edge Aortic Valve System.
Boston Scientific’s Cardiovascular segment accounts for around 40% of the company’s value, according to our estimates.
Boston Scientific Corporation (NYSE: BSX ) announced Tuesday after the close a delay to earlier timelines that were established for commercialization of the LOTUS Edge Aortic Valve System in Europe and ...
Shares of Boston Scientific took an unexpected dive on Tuesday after the Marlborough-based medical device maker cancelled a scheduled appearance at an investor conference without explanation. Boston Scientific (BSX) pulled out of the annual Piper Jaffray healthcare conference in New York, where two of the company’s investor relations executives had been scheduled to participate in a question-and-answer session Tuesday morning.
MARLBOROUGH, Mass., Nov. 28, 2017 /PRNewswire/ -- Boston Scientific (BSX) announces a delay to previously communicated timelines for commercialization of the LOTUS Edge™ Aortic Valve System* in Europe and the U.S. The company now expects to provide an update on the status of the LOTUS Edge Valve during its fourth quarter 2017 earnings conference call on February 1, 2018, as it continues to focus on manufacturing and regulatory milestones to support the long-term success of the Lotus platform. "We continue to see value in the unique benefits of the LOTUS Valve platform in treating patients with aortic stenosis," said Mike Mahoney, chairman and chief executive officer, Boston Scientific.
Boston Scientific (BSX) fell to the bottom of the S&P 500 on Tuesday, after it pulled out of a scheduled conference appearance. Boston Scientific slid $2.12, or $7.4, to $26.42, while the S&P 500 rose 25.62 points, or 0.98%, to 2627.04, notching a new record close. As last as last week, Boston Scientific had been scheduled to appear at the Piper Jaffary Annual Healthcare Conference.
Stock Monitor: Medtronic Post Earnings Reporting LONDON, UK / ACCESSWIRE / November 28, 2017 / Active-Investors' free earnings report on Boston Scientific Corp. (NYSE: BSX ) has freshly been issued to ...